The clinical relevance of dry powder inhaler performance for drug delivery

Respiratory Medicine

Volumn 108, Issue 8, 2014, Pages 1195-1203

  Demoly, Pascal ^a   Hagedoorn, Paul ^b   De Boer, Anne H ^b   Frijlink, Henderik W ^b  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Dry powder inhaler; Fine particle fraction; Inhaler resistance; Lung deposition

Indexed keywords

CORTICOSTEROID; AEROSOL; ANTIASTHMATIC AGENT; BRONCHODILATING AGENT;

AIRWAY; AIRWAY RESISTANCE; ARTICLE; BREATHING; DIFFUSION; DISEASE EXACERBATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRY POWDER INHALER; FLOW RATE; GEOMETRY; HUMAN; OROPHARYNX; OUTCOME ASSESSMENT; PARTICLE SIZE; PRIORITY JOURNAL; SEDIMENTATION; UPPER RESPIRATORY TRACT; ADMINISTRATION AND DOSAGE; AEROSOL; ASTHMA; CHEMISTRY; EQUIPMENT DESIGN; INHALATION; INHALATIONAL DRUG ADMINISTRATION; LUNG; PHARMACOKINETICS; PHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STANDARDS;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; DRY POWDER INHALERS; EQUIPMENT DESIGN; HUMANS; INHALATION; LUNG; PARTICLE SIZE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84906322938     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2014.05.009     Document Type: Article

References (54)

1. Global Initiative for Asthma (GINA) Global strategy for asthma prevention and management 2012 [cited 2013 Aug 20]; Available from: http://www.ginasthma. org/local/uploads/files/GINA-Report-March13.pdf
2. M.B. Dolovich, R.C. Ahrens, D.R. Hess, P. Anderson, R. Dhand, and J.L. Rau et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology Chest 127 2005 335 371
3. M.B. Dolovich, and R. Dhand Aerosol drug delivery: developments in device design and clinical use Lancet 377 2011 1032 1045
4. Aerosol Drug Management Improvement Team (ADMIT) The ADMIT webpage 2013 [cited 2013 Aug 20]; Available from: http://www.admit-online.info/en/
5. W. Vincken, P.R. Dekhuijzen, and P. Barnes The ADMIT series - issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD Prim Care Respir J - J Gen Pract Airw Group 19 2010 10 20
6. J. Denyer, K. Nikander, and N.J. Smith Adaptive aerosol delivery (AAD) technology Expert Opin Drug Deliv 1 2004 165 176
7. A. Fischer, J. Stegemann, G. Scheuch, and R. Siekmeier Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials Eur J Med Res 14 Suppl. 4 2009 71 77
8. P. Anderson Use of Respimat Soft Mist inhaler in COPD patients Int J Chron Obstruct Pulmon Dis 1 2006 251 259
9. I.M. Adcock, G. Caramori, and P.A. Kirkham Strategies for improving the efficacy and therapeutic ratio of glucocorticoids Curr Opin Pharmacol 12 2012 246 251
10. H. Chrystyn, and C. Niederlaender The Genuair(R) inhaler: a novel, multidose dry powder inhaler Int J Clin Pract 66 2012 309 317
11. E. Andrzej, and B.E. Malgorzata Easyhaler - ideal dry powder inhaler Pol Merkur Lekarski - Organ Pol Tow Lek 28 2010 307 310
12. M.E. Abdelrahim Emitted dose and lung deposition of inhaled terbutaline from Turbuhaler at different conditions Respir Med 104 2010 682 689
13. O. Selroos, L. Borgstrom, and J. Ingelf Performance of Turbuhaler(R) in patients with acute airway obstruction and COPD, and in children with asthma: understanding the clinical importance of adequate peak inspiratory flow, high lung deposition, and low in vivo dose variability Treat Respir Med 5 2006 305 315
14. M. Hoppentocht, P. Hagedoorn, H.W. Frijlink, and A.H. de Boer Technological and practical challenges of dry powder inhalers and formulations Adv Drug Deliv Rev 2014 10.1016/j.addr.2014.04.004
15. W. Azouz, and H. Chrystyn Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice Prim Care Respir J - J Gen Pract Airw Group 21 2012 208 213
16. H. Chrystyn, and D. Price Not all asthma inhalers are the same: factors to consider when prescribing an inhaler Prim Care Respir J - J Gen Pract Airw Group 18 2009 243 249
17. F. Lavorini, A. Magnan, J.C. Dubus, T. Voshaar, L. Corbetta, and M. Broeders et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD Respir Med 102 2008 593 604
18. T.H. Self, J.L. Wallace, C.M. George, A. Howard-Thompson, and S.D. Schrock Inhalation therapy: help patients avoid these mistakes J Fam Pract 60 2011 714 721
19. J. van der Palen, P. van der Valk, M. Goosens, K. Groothuis-Oudshoorn, and M. Brusse-Keizer A randomised cross-over trial investigating the ease of use and preference of two dry powder inhalers in patients with asthma or chronic obstructive pulmonary disease Expert Opin Drug Deliv 10 2013 1171 1178
20. R. Hodder, P.R. Reese, and T. Slaton Asthma patients prefer Respimat Soft Mist inhaler to Turbuhaler Int J Chron Obstruct Pulmon Dis 4 2009 225 232
21. M.J. Welch, H.S. Nelson, G. Shapiro, G.W. Bensch, W.N. Sokol, and J.A. Smith et al. Comparison of patient preference and ease of teaching inhaler technique for Pulmicort Turbuhaler versus pressurized metered-dose inhalers J Aerosol Med - Off J Int Soc Aerosols Med 17 2004 129 139
22. K. Sheth, J.A. Bernstein, W.R. Lincourt, K.K. Merchant, L.D. Edwards, and C.C. Crim et al. Patient perceptions of an inhaled asthma medication administered as an inhalation powder via the Diskus or as an inhalation aerosol via a metered-dose inhaler Ann Allergy Asthma Immunol - Off Publ Am Coll Allergy Asthma Immunol 91 2003 55 60
23. D. Price, A.J. Lee, E.J. Sims, L. Kemp, E.V. Hillyer, and A. Chisholm et al. Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study Prim Care Respir J - J Gen Pract Airw Group 22 2013 161 168
24. H. Chrystyn Do patients show the same level of adherence with all dry powder inhalers? Int J Clin Pract Suppl 2005 19 25
25. M. Thomas, D. Price, H. Chrystyn, A. Lloyd, A.E. Williams, and J. von Ziegenweidt Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control BMC Pulm Med 9 2009 1
26. M. Thomas, and A.E. Williams Are outcomes the same with all dry powder inhalers? Int J Clin Pract Suppl 2005 33 35
27. D. Brocklebank, F. Ram, J. Wright, P. Barry, C. Cates, and L. Davies et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature Health Technol Assess 5 2001 1 149
28. A.J. Hickey, T.B. Martonen, and Y. Yang Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols Pharm Acta Helv 71 1996 185 190
29. H.W. Frijlink, and A.H. De Boer Dry powder inhalers for pulmonary drug delivery Expert Opin Drug Deliv 1 2004 67 86
30. A.H. de Boer, P. Hagedoorn, D. Gjaltema, J. Goede, and H.W. Frijlink Air classifier technology (ACT) in dry powder inhalation part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler Int J Pharm 310 2006 81 89
31. L. Borgstrom On the use of dry powder inhalers in situations perceived as constrained J Aerosol Med - Off J Int Soc Aerosols Med 14 2001 281 287
32. L. Agertoft, and S. Pedersen Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children Am J Respir Crit Care Med 168 2003 779 782
33. S.P. Newman Aerosol deposition considerations in inhalation therapy Chest 88 1985 152S 160S
34. H.W. Frijlink, and A.H. de Boer Trends in the technology-driven development of new inhalation devices Drug Discov Today Technol 2 2005 47 57
35. O.S. Usmani, M.F. Biddiscombe, and P.J. Barnes Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size Am J Respir Crit Care Med 172 2005 1497 1504
36. S.P. Newman, G.R. Pitcairn, P.H. Hirst, R.E. Bacon, E. O'Keefe, and M. Reiners et al. Scintigraphic comparison of budesonide deposition from two dry powder inhalers Eur Respir J 16 2000 178 183
37. T. Ehtezazi, M.A. Horsfield, P.W. Barry, and C. O'Callaghan Dynamic change of the upper airway during inhalation via aerosol delivery devices J Aerosol Med - Off J Int Soc Aerosols Med 17 2004 325 334
38. P.J. Barnes Distribution of receptor targets in the lung Proc Am Thorac Soc 1 2004 345 351
39. M.V. White Muscarinic receptors in human airways J Allergy Clin Immunol 95 1995 1065 1068
40. H. Meurs, B.G. Dekkers, H. Maarsingh, A.J. Halayko, J. Zaagsma, and R. Gosens Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target Pulm Pharmacol Ther 26 2013 145 155
41. T. Pera, A. Zuidhof, J. Valadas, M. Smit, R.G. Schoemaker, and R. Gosens et al. Tiotropium inhibits pulmonary inflammation and remodelling in a guinea pig model of COPD Eur Respir J 38 2011 789 796
42. J. Milara, A. Serrano, T. Peiro, A. Gavalda, M. Miralpeix, and E.J. Morcillo et al. Aclidinium inhibits human lung fibroblast to myofibroblast transition Thorax 67 2012 229 237
43. L. Asking, C. Maayan, and G. Petterson Flutide Diskus less consistent than Pulmicort Turbuhaler with respect to in vitro fine particle dose proportionality Am J Respir Crit Care Med 163 2009 A441
44. L. Thorsson, S. Edsbacker, A. Kallen, and C.G. Lofdahl Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler Br J Clin Pharmacol 52 2001 529 538
45. H. Bisgaard, B. Klug, B.S. Sumby, and P.K. Burnell Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma Eur Respir J 11 1998 1111 1115
46. L. Borgstrom, L. Asking, and L. Thorsson Idealhalers or realhalers? A comparison of Diskus and Turbuhaler Int J Clin Pract 59 2005 1488 1495
47. W.H. DeHaan, and W.H. Finlay Predicting extrathoracic deposition from dry powder inhalers J Aerosol Sci 35 2004 309 331
48. D. Kohler The Novolizer: overcoming inherent problems of dry powder inhalers Respir Med 98 Suppl. A 2004 S17 S21
49. B.L. Laube, H.M. Janssens, F.H. de Jongh, S.G. Devadason, R. Dhand, and P. Diot et al. What the pulmonary specialist should know about the new inhalation therapies Eur Respir J 37 2011 1308 1331
50. J.P. de Koning Dry powder inhalation: technical and physiological aspects, prescribing and use: chapter 2: effect of resistance to airflow on the inspiratory flow curve 2001 University of Groningen Groningen, The Netherlands
51. T. Kondo, T. Tanigaki, G. Tazaki, H. Wanatabe, H. Ishii, and T. Tsunoda et al. Areguri 59 2010 950 955
52. T.T. Yang, S. Li, B. Wyka, and D. Kenyon Drug delivery performance of the mometasone furoate dry powder inhaler J Aerosol Med 14 2001 487 494
53. T. Weuthen, S. Roeder, P. Brand, B. Müllinger, and G. Scheuch In vitro testing of two formoterol dry powder inhalers at different flow rates J Aerosol Med 15 2002 292 303
54. Therapeutic Goods Administration Department of Health & Ageing Australian public assessment report for glycopyrronium (as bromide) 2013